Certepetide Fails to Improve PFS in Metastatic Pancreatic Cancer: ASCEND Trial
• The phase 2 ASCEND trial evaluated certepetide plus gemcitabine and nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma (PDAC).
• The addition of certepetide did not significantly improve progression-free survival (PFS) compared to chemotherapy alone, with a median PFS of 5.5 months in both arms.
• A possible signal of benefit in overall survival (OS) and objective response rate (ORR) was observed, warranting further investigation.
• Certepetide was found to be safe, and a further cohort study is ongoing to evaluate a second dose of certepetide.
Telix Pharmaceuticals' ProstACT GLOBAL Trial Advances Theranostic Approach for Advanced Prostate Cancer
• The ProstACT GLOBAL trial, sponsored by Telix Pharmaceuticals, is a Phase 3 study evaluating a novel radio antibody-drug conjugate (rADC) for advanced prostate cancer.
• The rADC targets prostate-specific membrane antigen (PSMA) on cancer cells, delivering radiation therapy selectively to tumors while sparing healthy tissue.
• The trial assesses the rADC's efficacy in improving overall and progression-free survival, safety, and quality of life in patients with progressive metastatic prostate cancer.
• This multinational, multicenter study builds on earlier phase trials, aiming to establish theranostics as a safe and effective treatment option.
© Copyright 2025. All Rights Reserved by MedPath